Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/13/23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian CancerGlobeNewsWire • 08/02/23
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023GlobeNewsWire • 07/28/23
Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023GlobeNewsWire • 07/14/23
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023GlobeNewsWire • 05/25/23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell CarcinomaGlobeNewsWire • 05/16/23
Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset BatiraxceptGlobeNewsWire • 05/08/23
Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual MeetingGlobeNewsWire • 04/26/23